Faeth Therapeutics, Inc. (FTH) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Faeth Therapeutics, Inc. (FTH) closed at USD 20.00 on 2026-10-14, a change of +109.9 % over the past year, with a market capitalization of USD 532.31M.

Faeth Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Faeth Therapeutics, Inc. key figures

Previous close

USD 20.00 (2026-10-14)

1-year change

+109.9 %

Market cap

USD 532.31M

Enterprise value

USD 346.46M

P/E ratio (trailing)

-0.35

P/E ratio (forward)

-4.59

EPS (trailing)

-58.72

EPS (forward)

-4.49

PEG ratio

n/a

Price to book

3.08

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

4.76

Employees

29

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Faeth Therapeutics, Inc.

Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Sensei Biotherapeutics, Inc. and changed its name to Faeth Therapeutics, Inc. in June 2026. The company was incorporated in 1999 and is headquartered in Rockville, Maryland.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Faeth Therapeutics, Inc. and compare it with other stocks.